Danaher price target lowered to $290 from $320 at TD Cowen

TD Cowen analyst Dan Brennan lowered the firm’s price target on Danaher to $290 from $320 and keeps an Outperform rating on the shares. The analyst said ongoing Bioprocess de-stock and new weakness from Emerging Biotech customers led to the cut to 20223 organic ex-COVID guidance, which along with the impact of cost cut actions also led to an EPS cut.